Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Agile Therapeutics, Inc. focuses on developing and commercializing innovative prescription contraceptive products, primarily its lead product, Twirla, a transdermal patch for birth control. The company operates primarily in the United States, leveraging its unique delivery system to differentiate itself in a competitive market dominated by traditional oral contraceptives.
Agile Therapeutics generates revenue primarily through the sale of its contraceptive patch, Twirla, which is priced competitively against traditional oral contraceptives. The company benefits from a unique delivery mechanism that offers convenience and adherence advantages, positioning it favorably in the contraceptive market.
Sales growth of Twirla driven by market penetration and physician adoption
Regulatory approvals for new contraceptive products
Partnerships or collaborations that expand distribution channels
Market dynamics in the contraceptive space, including competitive product launches
Regulatory changes affecting drug approval processes
Technological disruption from new contraceptive methods
Entry of generic competitors to Twirla
Innovations in contraceptive technology by larger pharmaceutical companies
Negative operating cash flow impacting liquidity
High operating losses leading to potential funding challenges
moderate - The demand for contraceptives can be influenced by economic conditions, as consumer spending on healthcare products may fluctuate with economic cycles.
minimal - Agile Therapeutics is not significantly affected by interest rates as it does not rely heavily on debt financing.
minimal - The company has a negative debt/equity ratio, indicating limited reliance on credit.
growth - Investors looking for high-growth potential in the healthcare sector, particularly in women's health.
high - The stock has shown significant volatility, evidenced by a 376.3% return over the last three months.
